Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) said ImmunoBON, its protein-based oral product for the treatment of allergies, was voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards in Germany.
The awards, held every year, are based on the Pharma Trend benchmark study, which seeks the views of 700 physicians, 100 pharmacists and 600 patients in Germany.
Launched in Germany and Austria earlier this year, ImmunoBON replicates the reduced allergic reactions seen in people who live on or close to livestock farms - the so-called 'farm effect'. It is most useful for people with mild allergies.
The latest data support its use as a treatment for birch and house dust mite allergies and the company said it is currently exploring its potential across a broader patient population.
Allergy Therapeutics chief executive Manuel Llobet said: "We are delighted that ImmunoBON has been recognised for its innovative approach to the treatment of allergy patients, particularly as the award is voted for by those we serve - doctors, pharmacists and patients.
"ImmunoBON is an exciting product that provides an over the counter option which fits very well with our portfolio philosophy to develop highly differentiated products with specific value-added for our patients.
“Following successful launches in Germany and Austria, we are looking forward to making ImmunoBON available to more patients, through additional country launches, and through research exploring its potential to treat additional allergies".